ALT CEO Jerome Benedict bought 15,000 shares at $3.14 on 2026-04-01; stock down -59.5% from 52-week high, company burning cash with -$19.0M net income.
Durso Jerome Benedict, the company's President and CEO, purchased 15,000 shares at $3.14, expanding his holdings by 46.2% to 47,500 shares. The purchase occurs while Altimmune trades at -59.5% from its 52-week high of $7.71, and the stock has declined -25.0% over the prior 30 days. The company's fundamentals remain challenged: Altimmune posted a -$19.0M net loss on $5.0K quarterly revenue and is unprofitable on a full-year basis, though annual revenue growth reached +105.0%. Against his own cross-ticker track record, this insider has achieved a 0.00% 90-day win rate across 2 prior open-market buys, with the most recent ALT purchase (2025-12-22) returning -19.0% at the 90-day mark. The pattern of repeated accumulation into a declining stock with negative earnings and minimal near-term revenue warrants monitoring of near-term execution and capital trajectory.
ALT CEO Jerome Benedict buys 20,000 shares at $3.54 (stock down 49.7% from 52-week high)
Jerome Benedict, President and CEO of Altimmune, purchased 20,000 shares at $3.54 on 2026-03-06, tripling his holdings from 12,500 to 32,500 shares. The purchase occurs at $3.54 while the stock trades 49.7% below its 52-week high of $7.71 and down 20.3% over the past 30 days. Altimmune remains unprofitable with a net loss of $-19,014,000.00 in its latest full fiscal year, though the company shows strong annual revenue growth of +105.0%. Benedict's prior open-market buy showed a +12.0% return within 30 days, though his track record lacks measurable positive outcomes at the 90-day mark. The timing and scale of this purchase merit monitoring given the company's unprofitability and recent significant stock decline.
Director Durso buys 12,500 shares of ALT at $4.13; company burning cash with -$19.0M net income.
Director Jerome Benedict Durso acquired 12,500 shares at $4.13, entering the company with an initial stake during a period of financial distress. Altimmune's latest quarter showed revenue of $5,000.00 with net income of -$19.0M and annual revenue contraction of -95.3%, indicating a company in severe operational decline. The stock trades at -50.7% from its 52-week high of $8.40 and has declined 13.9% over the past 30 days, though it is up 9.2% over 90 days. This purchase by a newly-vested director merits attention to governance and capital allocation patterns at a pre-revenue or near-zero-revenue stage biotech company.
